<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01715714</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-1341</org_study_id>
    <secondary_id>2011-001795-19</secondary_id>
    <secondary_id>DRKS00000753</secondary_id>
    <nct_id>NCT01715714</nct_id>
  </id_info>
  <brief_title>Statin Recapture Therapy Before Coronary Artery Bypass Grafting</brief_title>
  <acronym>StaRT-CABG</acronym>
  <official_title>Statin Recapture Therapy Before Coronary Artery Bypass Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with coronary artery disease requiring coronary artery bypass grafting (CABG) are at
      risk for postoperative complications after surgery. The StaRT-CABG trial is the first
      large-scale (2,630 patients) that will investigate whether an additional treatment with
      statins (lipid-lowering medication) in high doses before CABG surgery can reduce the
      incidence of major post-surgery complications including death, myocardial infarction and
      stroke. The StaRT-CABG trial will be recruiting patients from 8 cardiac surgery centres in
      Germany and is expected to provide relevant clinical data on the efficacy of this novel
      treatment in order to optimize the care for all patients undergoing CABG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with coronary artery disease (CAD) requiring coronary artery bypass grafting (CABG)
      are still at significant risk for postoperative major adverse cardiocerebral events (≈15%
      MACCE rate), with ≈3% of patients dying within 30 days of surgery. Recent clinical evidence
      shows that cardioprotection in patients receiving chronic statin treatment can be further
      improved by a high-dose statin 'recapture' therapy given shortly before an
      ischemia-reperfusion sequence, resulting in a 61% risk reduction for MACE at 30 days in
      patients undergoing PCI. Evaluation of this novel approach in the setting of CABG seems
      particularly promising, as myocardial injury, surgery-related inflammation and pre-existing
      patients' comorbidities play a pivotal role for poor clinical outcomes after CABG that may be
      improved by an acute statin recapture therapy. The StaRT-CABG trial is the first large-scale
      (n=2,630 CABG patients), multicentre (8 cardiac surgery centres), randomised, double-blind
      and placebo-controlled trial that aims to test whether an acute high-dose statin recapture
      therapy given shortly before CABG reduces the incidence of MACCE at 30 days after surgery
      (composite primary outcome: all-cause mortality; non-fatal myocardial infarction and
      cerebrovascular events). The StaRT-CABG trial is expected to provide highly relevant clinical
      data on the efficacy of this novel therapeutic approach in order to optimize the care for all
      CAD patients undergoing CABG with broad clinical implications on current clinical practice
      and existing guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiocerebral events (MACCE) within 30 days after CABG.</measure>
    <time_frame>30 days after Surgery</time_frame>
    <description>Composite endpoint consisting of (1) all-cause mortality, (2) non-fatal myocardial infarction (MI) and (3) non-fatal cerebrovascular event (stroke or TIA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>30 days after Surgery</time_frame>
    <description>Composite outcome consisting cardiac mortality and non-fatal MI within 30 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>within the first 15 days after surgery (plus or minus 5 days)</time_frame>
    <description>Length of stay on intensive care unit (ICU) and hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat coronary revascularisation</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Repeat coronary revascularisation (PCI or CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at 12 months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>All-cause mortality at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound Infections</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Surgical site wound infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>within the first 15 days after surgery (plus or minus 5 days)</time_frame>
    <description>New-onset postoperative atrial fibrillation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2630</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Statin Recapture Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral statin reload of patients at 12 and 2 hours before CABG using the maximal dose of the chronically prescribed statin* on admission. (*simvastatin 80 mg, atorvastatin 80 mg, fluvastatin 80 mg or pravastatin 40 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given orally 12 hrs and 2 hrs before CABG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin Recapture Therapy</intervention_name>
    <description>Given 12h and 2h before CABG</description>
    <arm_group_label>Statin Recapture Therapy</arm_group_label>
    <other_name>Simvastatin 80 mg</other_name>
    <other_name>Atorvastatin 80 mg</other_name>
    <other_name>Pravastatin 40 mg</other_name>
    <other_name>Fluvastatin 80 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given 12h and 2h before CABG.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients on chronic statin treatment (&gt;30 days) scheduled for isolated CABG, including
             on- or off-pump or repeat (redo's) revascularisation procedures

          2. Stable or unstable angina, including non ST-segment-elevation acute coronary syndrome
             (NSTE-ACS)

          3. Age ≥ 18 years

          4. Written informed consent

        Exclusion Criteria:

          1. Any concomitant cardiovascular procedure to CABG (i.e. valve, aortic or carotid
             surgery)

          2. Acute ST-segment-elevation myocardial infarction (STEMI)

          3. NSTE-ACS with cardiogenic shock warranting emergent salvage surgery within 12 hrs from
             hospital admission

          4. History of atrial fibrillation or muscle disease (myopathy)

          5. Current renal (creatinine&gt;2x upper limit of normal (ULN), dialysis, kidney transplant)
             or hepatic dysfunction (AST/ALT&gt;2x ULN, liver transplant or neoplasm)

          6. Inability of oral drug intake
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver J Liakopoulos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oliver J. Liakopoulos, MD, PhD</last_name>
    <phone>+49 221 478</phone>
    <phone_ext>32450</phone_ext>
    <email>oliver.liakopoulos@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petra Krause, MD</last_name>
    <phone>+49 221 478</phone>
    <phone_ext>88375</phone_ext>
    <email>petra.krause@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Center Freiburg-Bad Krozingen</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heart Center Bad Neustadt</name>
      <address>
        <city>Bad Neustadt An Der Saale</city>
        <state>Bayern</state>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arno Diegeler, Prof., MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Wilko Reents, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rüdiger Autschbach, MD, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Goetzenich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rüdiger Autschbach, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Center Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>NRW</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Gummmert, MD, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Jochen Börgermann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Gummert, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bochum</name>
      <address>
        <city>Bochum</city>
        <state>NRW</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justus Strauch, MD, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Mügge, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Haldenwang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver J Liakopoulos, MD, PhD</last_name>
      <phone>+49 221 478</phone>
      <phone_ext>32450</phone_ext>
      <email>oliver.liakopoulos@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Oliver J Liakopoulos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thorsten Wahlers, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Thielmann, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Matthias Thielmann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heinz Jakob, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Wendt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Muenster</name>
      <address>
        <city>Muenster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios Heart Center Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <state>NRW</state>
        <zip>42117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.start-cabg.de</url>
    <description>StaRT CABG Homepage</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2012</study_first_submitted>
  <study_first_submitted_qc>October 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2012</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>PD Dr. Oliver J. Liakopoulos</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Statins</keyword>
  <keyword>Coronary Artery Bypass Grafting</keyword>
  <keyword>Cardiac Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Fluvastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

